1. Home
  2. SOHU vs LYEL Comparison

SOHU vs LYEL Comparison

Compare SOHU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$12.84

Market Cap

337.1M

Sector

Technology

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$15.01

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
LYEL
Founded
1996
2018
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.1M
320.1M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
SOHU
LYEL
Price
$12.84
$15.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$20.00
$30.60
AVG Volume (30 Days)
59.9K
248.1K
Earning Date
05-18-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$1.61
N/A
Revenue Next Year
$3.78
$8,712.13
P/E Ratio
$1.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$9.03
52 Week High
$17.30
$45.00

Technical Indicators

Market Signals
Indicator
SOHU
LYEL
Relative Strength Index (RSI) 48.99 53.05
Support Level $11.61 $11.59
Resistance Level $15.91 $19.02
Average True Range (ATR) 0.49 1.48
MACD 0.16 0.50
Stochastic Oscillator 79.87 65.29

Price Performance

Historical Comparison
SOHU
LYEL

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: